Format

Send to

Choose Destination
Respir Investig. 2016 May;54(3):156-61. doi: 10.1016/j.resinv.2015.10.001. Epub 2015 Dec 15.

Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis: A prospective, single-arm study.

Author information

1
Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: b980013@yahoo.co.jp.
2
Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: himatsushima@sunny.ocn.ne.jp.
3
Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: obatomohiro@hotmail.co.jp.
4
Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: blackberry_wine1218@yahoo.co.jp.
5
Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: mizu_mina@hotmail.com.
6
Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: skyfield1021@gmail.com.
7
Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: tn1230bungo@yahoo.co.jp.
8
Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: hondakojiro78@gmail.com.

Abstract

BACKGROUND:

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with few treatment options. The efficacy of N-acetylcysteine in patients with IPF remains controversial. The aim of this research was to investigate the efficacy of inhaled N-acetylcysteine.

METHODS:

This study was designed as a single-center, single-arm, prospective clinical trial. Each patient who had IPF received 352.4mg of inhaled N-acetylcysteine twice daily.

RESULTS:

In total, 28 patients were enrolled. The mean values of the respiratory function parameters at the initiation of therapy were as follows: forced vital capacity (FVC), 2.27L and %FVC, 76.2%. The mean change in FVC during 26 weeks prior to the inhaled N-acetylcysteine therapy was -170mL, a significant decrease (p=0.019). The mean change in FVC during 26 weeks after the initiation of inhaled N-acetylcysteine therapy was -70mL (p=0.06). When the patients were classified into two groups according to the degree of decline in FVC (≥100mL vs. <100mL) during the 26-week period prior to the initiation of therapy, inhaled N-acetylcysteine showed a greater efficacy in attenuating FVC decline in the ≥100-mL group than in the <100-mL group.

CONCLUSIONS:

Inhaled N-acetylcysteine therapy was effective in patients with mild-to-moderate IPF and was more beneficial in patients who had greater declines in FVC before the initiation of therapy. (UMIN title: Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis, UMIN000016706, 2015/03/04.).

KEYWORDS:

Forced vital capacity; Idiopathic pulmonary fibrosis; Inhalation; Krebs von den Lungen-6; N-acetylcysteine

PMID:
27108010
DOI:
10.1016/j.resinv.2015.10.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center